Antimicrobial Resistance During the SARS-CoV-2 (COVID-19) Pandemic

Recruiting

• Conditions: COVID-19

• Registration Number: NCT06334731
• Lead Sponsor: Methodist Health System

Brief Summary

Assess the incidence and rates of resistant pathogens prior to and during the COVID-19 pandemic.

Detailed Description

The COVID-19 pandemic accelerated/exacerbated resistance rates for key pathogens. Specifically, incidence of extended-spectrum beta-lactamase producing Enterobacteriaceae (ESBLPE), carbapenem-resistant bacteria (CRB), methicillin-resistant Staphyloccoccus aureus (MRSA), vancomycin-resistant Enterococci (VRE), and C. difficile infections (CDI) will be higher in the pandemic time period (Pandemic, March 2020 - February 2025) compared to the pre-pandemic period (Pre-Pandemic, March 2018 - February 2020).

Study Timeline

• Study Start: 2021-07-06
• Study First Submitted: 2022-10-21
• Status Verified: 2024-03
• Study First Submitted QC: 2024-03-26
• Last Update Submitted: 2024-03-26
• Study First Posted: 2024-03-28
• Last Update Posted: 2024-03-28
• Primary Completion: 2024-12
• Study Completion: 2024-12

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 400

Inclusion Criteria

• • Patients admitted to Methodist Richardson, Methodist Mansfield, Methodist Charlton, or Methodist Dallas Medical Centers between March 2018 and August 2021.

  • >18 years old

Exclusion Criteria

• • Outpatient visit

  • Not admitted to an inpatient or observation status

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Incidence of third generation cephalosporin-resistant bacteria (3GCRB)	5 Months	Incidence of third generation cephalosporin-resistant bacteria (3GCRB)

Secondary Outcome Measures

Name	Time	Method
Incidence of CRB	5 Months	Incidence of CRB
Incidence of other pathogens	August 2021	* MRSA; * VRE; * CDI
Incidence of ESBLPE	5 months	Incidence of ESBLPE
Incidence of nosocomial infections	5 Months	* Catheter-associated urinary tract infection (CAUTI); * Central line-associated bloodstream infection (CLABSI); * Possible ventilator-associated pneumonia (PVAP)
Incidence of clinical outcomes	5 Months	death, recovery, long-term care facility, etc.

Trial Locations

Locations (1)

Methodist Dallas Medical Center; 🇺🇸 Dallas, Texas, United States